Ownership history in Resolute Advisors LLC · 18 quarters on record
This page tracks every 13F SEC filing in which Resolute Advisors LLC reported a position in Abcellera Biologics In F (ABCL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | UNCHANGED | 57,526 | — | 0% | 0.06% | $197K | $3.42 |
| 2025 Q3 | UNCHANGED | 57,526 | — | 0% | 0.07% | $289K | $5.03 |
| 2025 Q2 | REDUCED | 57,526 | -4,050 | -6.6% | 0.05% | $197K | $3.43 |
| 2025 Q1 | UNCHANGED | 61,576 | — | 0% | 0.04% | $137K | $2.23 |
| 2024 Q4 | UNCHANGED | 61,576 | — | 0% | 0.04% | $180K | $2.93 |
| 2024 Q3 | ADDED | 61,576 | +4,050 | +7.0% | 0.03% | $160K | $2.60 |
| 2024 Q2 | UNCHANGED | 57,526 | — | 0% | 0.04% | $170K | $2.96 |
| 2024 Q1 | UNCHANGED | 57,526 | — | 0% | 0.05% | $261K | $4.53 |
| 2023 Q4 | UNCHANGED | 57,526 | — | 0% | 0.04% | $328K | $5.71 |
| 2023 Q3 | UNCHANGED | 57,526 | — | 0% | 0.04% | $265K | $4.60 |
As of 2025 Q4 — sorted by position size